2. Academic Validation
  3. PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML

PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML

  • bioRxiv. 2025 Oct 2:2025.09.30.679569. doi: 10.1101/2025.09.30.679569.
Negar Khazan 1,  Cameron Wa Snyder 1,  Chandhana Ravi 1,  Elizabeth Lamere 2,  Niloy A Singh 1 2,  Manoj K Khera 3,  Jane Liesveld 2,  Srinivasan Ekambaram 4,  Nikolay V Dokholyan 4 5 6,  Myla Strawderman 7,  Kyu Kwang Kim 1,  Rachael Rowswell-Turner 1,  Michael W Becker 2,  Richard G Moore 1,  Rakesh K Singh 1
Affiliations

Affiliations

  • 1 Department of Gynecologic Oncology, University of Rochester Medical Center, Rochester, NY, 14642.
  • 2 Department of Medicine, University of Rochester Medical Center, Rochester, NY, 14642.
  • 3 Presude Lifesciences Private Limited, Delhi, India.
  • 4 Department of Neurology, University of Virginia, School of Medicine, Charlottesville, VA 22903, USA.
  • 5 Department of Neuroscience, University of Virginia, School of Medicine, Charlottesville, VA 22903, USA.
  • 6 Department of Biomedical Engineering, University of Virginia, School of Medicine, Charlottesville, VA 22903, USA.
  • 7 Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, 14642.
PMID: 41256437 DOI: 10.1101/2025.09.30.679569
Abstract

Acute Myeloid Leukemia (AML) is a life-threatening hematologic malignancy. Despite recent therapeutic advances, rising incidence rates emphasize the urgent need for identification of new targets and therapies. Roles of interleukin receptor-associated kinases IRAK1/4 are emerging in hematologic and solid malignancies. In AML, IRAK4 mRNA is overexpressed at diagnosis, relapses, in residual disease, and in FLT3-ITD-mutant cells, MDS, MPN, and MDS/MPN-negative subtypes. Compared with hematopoietic stem cells, IRAK4 is elevated in t(15;17), inv(16)/t(16;16), and t(11q23)/MLL subtypes, correlating with poor survival. Here, we disclose anti-AML activity of PSP-0119, a novel IRAK4 PROTAC degrader. PSP-0119, inhibited IRAK4 kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. In-silico docking revealed interactions in CRBN/IRAK4/PSP-0119 ternary complex. PSP-0119 degraded IRAK4 in FLT3-mutant AML cell lines sparing FLT3-wild-type AML cells, FLT3-wild-type patient samples, and normal bone-marrow. Bulk-seq of PSP-0119 treated MOLM-13 cells revealed downregulation of eNOS, a poor AML prognosticator. PSP-0119 suppressed colony formation, cell viability, and MOLM-13 xenograft growth, and synergized with IRAK1 covalent inhibitor JH-X-119-01. PSP-0119 is metabolically stable, retaining 71% of parent compound at 60 minutes in human liver microsomes. In summary, IRAK4 degradation via PSP-0119 as a promising therapeutic strategy for treatment of FLT3-mutant AML.

Figures
Products